Benitec Biopharma Ltd ADR

Yahoo Finance • 11 days ago

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Benitec Biopharma Inc. (NASDAQ:BNTC) is one of the best breakout stocks to invest in. On November 4, an analyst at Citizens JMP raised the stock’s price target to $22 from $20 while reiterating an Outperform rating. The price target hike f... Full story

Yahoo Finance • 14 days ago

Benitec GAAP EPS of -$0.22

* Benitec press release [https://seekingalpha.com/pr/20308734-benitec-biopharma-releases-first-quarter-2026-financial-results-and-provides-operational] (BNTC [https://seekingalpha.com/symbol/BNTC]): Q1 GAAP EPS of -$0.22. * Total Expen... Full story

Yahoo Finance • 14 days ago

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

–Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration (FDA) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301– –Positive i... Full story

Yahoo Finance • 17 days ago

Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others

santiphotois / Getty Images In the past week or so, beneficial owners Carl Icahn and Mario Gabelli made some big bets in Monro Inc. (NASDAQ: MNRO) and Gabelli Healthcare & WellnessRx Trust (NYSE: GRX), respectively. Meanwhile, another 10%... Full story

Yahoo Finance • 23 days ago

Benitec Biopharma prices $100M stock offering

* Benitec Biopharma (BNTC [https://seekingalpha.com/symbol/BNTC]) priced [https://seekingalpha.com/pr/20295927-benitec-biopharma-inc-announces-pricing-of-100-million-common-stock-offering] its underwritten public offering of ~5.93M share... Full story

Yahoo Finance • 23 days ago

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story

Yahoo Finance • 23 days ago

Benitec Biopharma Inc. Announces Proposed Public Offering

HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story

Yahoo Finance • 26 days ago

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Fast Track Designation was granted for BB-301 following FDA review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for BB-301 BB-301 has also been granted Orphan Drug Designat... Full story

Yahoo Finance • 26 days ago

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

Benitec Biopharma Inc. -Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025- HAYWARD, Calif., N... Full story

Yahoo Finance • 26 days ago

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story

Yahoo Finance • 2 months ago

Benitec GAAP EPS of -$1.05 beats by $0.72

* Benitec press release [https://seekingalpha.com/pr/20240290-benitec-biopharma-releases-full-year-2025-financial-results-and-provides-operational-update] (NASDAQ:BNTC [https://seekingalpha.com/symbol/BNTC]): FY GAAP EPS of -$1.05 beats... Full story

Yahoo Finance • 2 months ago

Benitec Biopharma files $200M mixed securities shelf

* Benitec Biopharma (NASDAQ:BNTC [https://seekingalpha.com/symbol/BNTC]) filed $200M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10439771] MORE ON BENITEC * Seeking Alpha’s Quant Rating on Benitec [https://see... Full story

Yahoo Finance • 2 months ago

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment StudyExpected in Q4 2025 HAYWARD, Calif., Sept... Full story

Yahoo Finance • 3 months ago

Amkor Technology Reaches Analyst Target Price

In recent trading, shares of Amkor Technology Inc. (Symbol: AMKR) have crossed above the average analyst 12-month target price of $41.00, changing hands for $41.19/share. When a stock reaches the target an analyst has set, the analyst log... Full story

Yahoo Finance • 4 months ago

Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid clinical progress

Benitec Biopharma Inc. (NASDAQ:BNTC), a biotechnology company specializing in gene therapies, has been making significant strides in its clinical development programs, particularly with its lead candidate BB-301 for the treatment of oculo... Full story

Yahoo Finance • 5 months ago

Benitec BioPharma stock maintains Market Outperform rating at JMP

Investing.com - Benitec BioPharma (NASDAQ:BNTC), currently trading at $13.84, maintained its Market Outperform rating and $20.00 price target in a research note from JMP Securities on Thursday. According to InvestingPro data, analysts’ tar... Full story

Yahoo Finance • 5 months ago

Cowen initiates Benitec BioPharma stock with Buy rating on OPMD treatment

Investing.com - TD Cowen initiated coverage on Benitec BioPharma (NASDAQ:BNTC) with a Buy rating on Monday. The clinical-stage biotechnology company, currently valued at $346 million, has seen its shares surge over 12% in the past week. T... Full story

Yahoo Finance • 8 months ago

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with... Full story

Yahoo Finance • 9 months ago

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scienti... Full story

Yahoo Finance • 2 years ago

Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its propriet... Full story